YingHuangMD

Anatomic Pathology, Clinical Pathology

Physician

Dr. Huang is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

PubMed

212 citations
Evaluation and Comparison of Food Records, Recalls, and Frequencies for Energy and Protein Assessment by Using Recovery Biomarkers
Ross L. Prentice, Yasmin Mossavar-Rahmani, Ying Huang, Linda Van Horn, Shirley A.A. Beresford
American Journal of Epidemiology. 2011-09-01
180 citations
High-throughput quantitative analysis of HIV-1 and SIV-specific ADCC-mediating antibody responses.
Justin Pollara, Lydia Hart, Faraha Brewer, Joy Pickeral, Beverly Z. Packard
Cytometry. Part A. 2011-07-06
242 citations
Magnitude and Breadth of the Neutralizing Antibody Response in the RV144 and Vax003 HIV-1 Vaccine Efficacy Trials
David C. Montefiori, Chitraporn Karnasuta, Ying Huang, Hasan Ahmed, Peter B. Gilbert
The Journal of Infectious Diseases. 2012-08-01

Abstracts/Posters

Microrna-191 Regulates T-Cell Clonal Expansion during Graft-Versus-Host Disease
Ying Huang, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

$CARVYKTI™ (Ciltacabtagene Autoleucel) Receives Approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma$
CARVYKTI™ (Ciltacabtagene Autoleucel) Receives Approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for the Treatment of Patients with Relapsed or Refractory Multiple MyelomaSeptember 29th, 2022
Legend Biotech Announces Phase 1b/2 Study Data of Cilta-Cel, an Investigational BCMA CAR-T, Showing Early, Deep, and Durable Responses in Heavily Pretreated Patients with Multiple MyelomaDecember 5th, 2020